Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.

ABSTRACT:

Background

Complete pathological response to neoadjuvant treatment (NAT) in breast cancer is associated with prolonged survival. Compared to other breast cancer immunophenotypes, luminal tumors are the least chemosensitive with low rates of pathological response within this molecular subtype. Thus, finding predictors of response in this subset remains challenging. The emerging concept of low human epidermal growth factor receptor 2 (HER2) expression has led to a repurpose of the current prognostic system. Little is known about its correlation with response to NAT.

Objectives

This study aims to evaluate predictors of response in early-stage luminal breast cancer receiving neoadjuvant chemotherapy.

Design

A total of 252 luminal patients who received NAT were retrospecti

SUBMITTER: Miras I 

PROVIDER: S-EPMC11672595 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature